From the source
- Alphabet's
Isomorphic Labs has closed a $5 billion investment led by Greenoaks and Sequoia Capital to speed up AI-driven drug discovery.
- More than a half-dozen backers joined the round, including parent Alphabet, which the company says made a "significant investment" through its GV and CapitalG funds.
- Isomorphic offers a software platform called the Isomorphic Labs Drug Design Engine, or IsoDDE, which uses AI to speed up several tasks in developing new medicines, and the unit says multiple pharmaceutical companies already use it to power drug discovery programs.
- IsoDDE speeds up the search for binding pockets on a target protein and, when none exist, helps researchers develop compounds that cause the protein to form them.
- The software also skips the step of creating 3D protein models for FEP algorithms, which requires freezing a protein in a crystal and scanning it with X-ray equipment, and Isomorphic says it can generate higher-quality output than FEP.
- Chief Executive Demis Hassabis said the round lets the company build foundational biology models, deepen its disease understanding and drive its first therapeutic programs toward clinical trials.
- Isomorphic added that it plans to build new bioengineering infrastructure and grow its partner ecosystem.